Ibrutinib in Chronic Lymphocytic Leukemia Deemed Not Cost-Effective by ICER Standards

No direct comparison between ibrutinib and chemoimmunotherapy as a first-line treatment exists.

from Latest articles from Cancer Therapy Advisor News https://ift.tt/2By4Now